These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 12629339)

  • 21. The presence of positive surgical margins in patients with organ-confined prostate cancer results in biochemical recurrence at a similar rate to that in patients with extracapsular extension and PSA ≤ 10 ng/ml.
    Eminaga O; Hinkelammert R; Titze U; Abbas M; Eltze E; Bettendorf O; Semjonow A
    Urol Oncol; 2014 Jan; 32(1):32.e17-25. PubMed ID: 23434425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control.
    Pound CR; Partin AW; Epstein JI; Walsh PC
    Urol Clin North Am; 1997 May; 24(2):395-406. PubMed ID: 9126237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors of positive surgical margin and biochemical recurrence of patients treated with radical prostatectomy: a single-center 10-year report.
    Li K; Li H; Yang Y; Ian LH; Pun WH; Ho SF
    Chin Med J (Engl); 2011 Apr; 124(7):1001-5. PubMed ID: 21542957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are prostate carcinoma clinical stages T1c and T2 similar?
    Billis A; Magna LA; Watanabe IC; Costa MV; Telles GH; Ferreira U
    Int Braz J Urol; 2006; 32(2):165-71. PubMed ID: 16650293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The outcome of patients with pathological Gleason score >or=8 prostate cancer after radical prostatectomy.
    Rodriguez-Covarrubias F; Larre S; De La Taille A; Abbou CC; Salomon L
    BJU Int; 2008 Feb; 101(3):305-7. PubMed ID: 17941921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Positive Surgical Margins after Radical Prostatectomy on Disease Progression and Adjuvant Treatment in Pathologically Localized Prostate Cancer.
    Tomasković I; Milicić V; Tomić M; Ruzić B; Ulamec M
    Coll Antropol; 2015 Sep; 39(3):697-700. PubMed ID: 26898068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biochemical recurrence after radical prostatectomy: multiplicative interaction between surgical margin status and pathological stage.
    Budäus L; Isbarn H; Eichelberg C; Lughezzani G; Sun M; Perrotte P; Chun FK; Salomon G; Steuber T; Köllermann J; Sauter G; Ahyai SA; Zacharias M; Fisch M; Schlomm T; Haese A; Heinzer H; Huland H; Montorsi F; Graefen M; Karakiewicz PI
    J Urol; 2010 Oct; 184(4):1341-6. PubMed ID: 20723925
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recurrence after radical prostatectomy for organ-confined prostate cancer.
    Scheepe JR; Vis AN; Mickisch GH
    Onkologie; 2003 Aug; 26(4):330-3. PubMed ID: 12972697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A close surgical margin after radical prostatectomy is an independent predictor of recurrence.
    Lu J; Wirth GJ; Wu S; Chen J; Dahl DM; Olumi AF; Young RH; McDougal WS; Wu CL
    J Urol; 2012 Jul; 188(1):91-7. PubMed ID: 22578729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy.
    Blute ML; Bostwick DG; Bergstralh EJ; Slezak JM; Martin SK; Amling CL; Zincke H
    Urology; 1997 Nov; 50(5):733-9. PubMed ID: 9372884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics of positive surgical margins in robotic-assisted radical prostatectomy, open retropubic radical prostatectomy, and laparoscopic radical prostatectomy: a comparative histopathologic study from a single academic center.
    Albadine R; Hyndman ME; Chaux A; Jeong JY; Saab S; Tavora F; Epstein JI; Gonzalgo ML; Pavlovich CP; Netto GJ
    Hum Pathol; 2012 Feb; 43(2):254-60. PubMed ID: 21820147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
    Raj GV; Partin AW; Polascik TJ
    Cancer; 2002 Feb; 94(4):987-96. PubMed ID: 11920467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer.
    Ramos CG; Carvalhal GF; Smith DS; Mager DE; Catalona WJ
    J Urol; 1999 May; 161(5):1525-9. PubMed ID: 10210388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
    Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
    Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Time trends in case selection, stage and prostate-specific antigen recurrence after radical prostatectomy: a multicentre audit.
    Winkler MH; Khan FA; Hoh IM; Okeke AA; Sugiono M; McInerney P; Boustead GB; Persad R; Kaisary AV; Gillatt DA
    BJU Int; 2004 Apr; 93(6):725-9. PubMed ID: 15049980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting factors for biochemical recurrence and oncological outcomes following laparoscopic radical prostatectomy in Rajavithi Hospital, Thailand.
    Viriyasiripong S; Akarasakul D; Thaidamrong T; Doungkae S
    J Med Assoc Thai; 2013 May; 96(5):569-74. PubMed ID: 23745312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Importance of margin extent as a predictor of outcome after adjuvant radiotherapy for Gleason score 7 pT3N0 prostate cancer.
    Valicenti RK; Chervoneva I; Gomella LG
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1093-7. PubMed ID: 15001249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of pT2 subdivisions in the TNM staging system for prostate cancer.
    Hong SK; Han BK; Chung JS; Park DS; Jeong SJ; Byun SS; Choe G; Lee SE
    BJU Int; 2008 Nov; 102(9):1092-6. PubMed ID: 18671786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
    Amling CL; Blute ML; Bergstralh EJ; Seay TM; Slezak J; Zincke H
    J Urol; 2000 Jul; 164(1):101-5. PubMed ID: 10840432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.